Tags

Type your tag names separated by a space and hit enter

The use of antibody engineering to create novel drugs that target N-methyl-D-aspartate receptors.
Curr Drug Targets. 2001 Sep; 2(3):331-45.CD

Abstract

According to a recent World Health Organization survey, there are over four hundred million people worldwide suffering from mental and neurological disorders; schizophrenia affects some forty-five million people, and unipolar major depression ranked fifth in major causes of disability and death. Clearly it is of the utmost importance to develop new, effective, and safe neuro-pharmaceuticals with this increasing "global burden of disease". To this end, we have developed a strategy of generating monoclonal antibodies that act as modulators of the cell-surface central nervous system receptor-ion channel complexes. In this review we will focus on the generation and characterization of a monoclonal antibody that acts as a partial agonist to the N-methyl-D-aspartate receptor. The creation of peptide mimetics, derived from this monoclonal antibody, that may be useful as cognitive enhancers and protect neurons hypoxic and ischemic insults caused by stroke, will also be discussed.

Authors+Show Affiliations

Nyxis Neurotherapies, Inc, and The Chicago Institute for Neurosurgery and Neuroresearch, Chicago, IL 60614, USA. j-moskal@nwu.eduNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11554557

Citation

Moskal, J R., et al. "The Use of Antibody Engineering to Create Novel Drugs That Target N-methyl-D-aspartate Receptors." Current Drug Targets, vol. 2, no. 3, 2001, pp. 331-45.
Moskal JR, Yamamoto H, Colley PA. The use of antibody engineering to create novel drugs that target N-methyl-D-aspartate receptors. Curr Drug Targets. 2001;2(3):331-45.
Moskal, J. R., Yamamoto, H., & Colley, P. A. (2001). The use of antibody engineering to create novel drugs that target N-methyl-D-aspartate receptors. Current Drug Targets, 2(3), 331-45.
Moskal JR, Yamamoto H, Colley PA. The Use of Antibody Engineering to Create Novel Drugs That Target N-methyl-D-aspartate Receptors. Curr Drug Targets. 2001;2(3):331-45. PubMed PMID: 11554557.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The use of antibody engineering to create novel drugs that target N-methyl-D-aspartate receptors. AU - Moskal,J R, AU - Yamamoto,H, AU - Colley,P A, PY - 2001/9/14/pubmed PY - 2002/2/20/medline PY - 2001/9/14/entrez SP - 331 EP - 45 JF - Current drug targets JO - Curr Drug Targets VL - 2 IS - 3 N2 - According to a recent World Health Organization survey, there are over four hundred million people worldwide suffering from mental and neurological disorders; schizophrenia affects some forty-five million people, and unipolar major depression ranked fifth in major causes of disability and death. Clearly it is of the utmost importance to develop new, effective, and safe neuro-pharmaceuticals with this increasing "global burden of disease". To this end, we have developed a strategy of generating monoclonal antibodies that act as modulators of the cell-surface central nervous system receptor-ion channel complexes. In this review we will focus on the generation and characterization of a monoclonal antibody that acts as a partial agonist to the N-methyl-D-aspartate receptor. The creation of peptide mimetics, derived from this monoclonal antibody, that may be useful as cognitive enhancers and protect neurons hypoxic and ischemic insults caused by stroke, will also be discussed. SN - 1389-4501 UR - https://www.unboundmedicine.com/medline/citation/11554557/The_use_of_antibody_engineering_to_create_novel_drugs_that_target_N-methyl-D-aspartate_receptors L2 - http://www.eurekaselect.com/65021/article DB - PRIME DP - Unbound Medicine ER -